Optovue Q2 and First Six Month Revenue 2010 Up 57% Over 2009

FREMONT, Calif., Sept. 24 /PRNewswire/ -- Optovue, the company that launched the first FDA cleared fourier/spectral domain OCT in the US, announced its second quarter revenue results for 2010 grew 57% over the same period in fiscal 2009. This also puts the first six months of 2010 at a 57% revenue increase over the same period in 2009.

"Following our 57% revenue growth in Q1 over prior year, our six month year-to-date revenue growth for 2010 is holding very strong," stated Gordon Wong, Vice President of Finance for Optovue. "With the recent FDA clearance of the Normative Database for the RTVue FD-OCT system and the strong growth in the sales of iVue compact OCT systems, the remainder of 2010 is on track to significantly exceed forecast."

About RTVue and iVue

RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician.

About Optovue (www.optovue.com)

Optovue Incorporated is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA and European operations in Heidelberg, Germany.

SOURCE Optovue Incorporated